Brain Dopamine Receptors: A Primer on Their Current Status, Basic and Clinical
The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Abstract
Recent progress in understanding the molecular biology and pharmacology of dopamine receptors in mammalian brain has been remarkable and can serve as a basis for psychiatrically relevant research. The most prevalent central dopaminergic receptors, types D1 and D2, have been cloned, and their gene and peptide sequences and structures have been proposed. Novel gene products that resemble either D1 (D5) or D2 (D3, D4) receptors also have been identified, their tissue distributions described, and their pharmacology characterized, mainly in gene-transfected cultured cells. These receptors belong to a superfamily of membrane proteins with seven membrane-spanning regions and an intracytoplasmic segment that interacts with G-proteins and other molecular elements of neurotransmission effector systems. Progress has been made toward developing agonists and antagonists for specific dopamine receptors. Recent discoveries have greatly stimulated clinical studies in neurogenetics, neuropathophysiology, and neuroradiology. New knowledge of receptor and effector components of brain dopaminergic neurotransmission systems is yielding revolutionary insights into the complexity of molecular neurotransmission. Innovative models for the rational design of novel neuropsychotropic agents and for seeking pathoetiologic contributions to major psychiatric and neurological disorders are anticipated. The discovery and definition of new gene products now require long-term efforts to clarify their physiology and to develop a pharmacology of novel dopamine receptors and their effectors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Functional architecture of basal ganglia circuits: neural substrates of parallel processing
Alexander, G. E., & Crutcher, M. D. (1990) · Trends in Neurosciences · doi:10.1016/0166-2236(90)90107-l · Cited by 4,131
D 1 and D 2 Dopamine Receptor-regulated Gene Expression of Striatonigral and Striatopallidal Neurons
Gerfen, C. R., Engber, T. M., Mahan, L. C., Susel, Z., Chase, T. N., Monsma, F. J., & Sibley, D. R. (1990) · Science · doi:10.1126/science.2147780 · Cited by 2,967
Cellular basis of working memory
Goldman-Rakic, P. S. (1995) · Neuron · doi:10.1016/0896-6273(95)90304-6 · Cited by 2,663
Dopamine Receptor Binding Predicts Clinical and Pharmacological Potencies of Antischizophrenic Drugs
Creese, I., Burt, D. R., & Snyder, S. H. (1976) · Science · doi:10.1126/science.3854 · Cited by 2,220
Antipsychotic drug doses and neuroleptic/dopamine receptors
SEEMAN, P., LEE, T., CHAU-WONG, M., & WONG, K. (1976) · Nature · doi:10.1038/261717a0 · Cited by 1,622
Neurotransmitters and neuromodulators in the basal ganglia
Graybiel, A. M. (1990) · Trends in Neurosciences · doi:10.1016/0166-2236(90)90104-i · Cited by 1,576
The role of dopamine in locomotor activity and learning
Beninger, R. J. (1983) · Brain Research Reviews · doi:10.1016/0165-0173(83)90038-3 · Cited by 848
Dopamine Receptor Binding Enhancement Accompanies Lesion-Induced Behavioral Supersensitivity
Creese, I., Burt, D. R., & Snyder, S. H. (1977) · Science · doi:10.1126/science.877576 · Cited by 712
Presynaptic regulation of neurotransmitter release in the brain: Facts and hypothesis
Chesselet, M.-F. (1984) · Neuroscience · doi:10.1016/0306-4522(84)90058-7 · Cited by 577
Molecular neurobiology of dopaminergic receptors
Sibley, D. R., Monsma, F. J., & Shen, Y. (1993) · International review of neurobiology · doi:10.1016/s0074-7742(08)60573-5 · Cited by 255
Cited by
Targeting the dopamine D1 receptor in schizophrenia: insights for cognitive dysfunction
Goldman-Rakic, P., Castner, S., Svensson, T., Siever, L., & Williams, G. (2004) · Psychopharmacology · doi:10.1007/s00213-004-1793-y · Cited by 544
“Cloning of the human dopamine receptors revealed the homology between the D1 and D5 subtypes of the D1 family and the D2, D3, and D4 receptor subtypes of the D2 family as well as their molecular properties (Baldessarini and Tarazi 1996; Lachowicz and Sibley 1997; Neve and Neve 1997).”
BackgroundModern antipsychotic drugs: a critical overview
Gardner, D. M. (2005) · Canadian Medical Association Journal · doi:10.1503/cmaj.1041064 · Cited by 422
Cannabidiol, a Cannabis sativa constituent, as an antipsychotic drug
Zuardi, A. W., Crippa, J. A. S., Hallak, J. E. C., Moreira, F. A., & Guimarães, F. S. (2006) · Brazilian Journal of Medical and Biological Research · doi:10.1590/s0100-879x2006000400001 · Cited by 402
Baldessarini, R. J. (2013) · doi:10.1007/978-1-4614-3710-9 · Cited by 365
Self-citationComparative postnatal development of dopamine D1, D2 and D4 receptors in rat forebrain
Tarazi, F. I., & Baldessarini, R. J. (2000) · International Journal of Developmental Neuroscience · doi:10.1016/s0736-5748(99)00108-2 · Cited by 327
“Higher levels of D1 than D2 receptors occur in the frontal cortex, and there is selective expression of D2 receptors in anterior pituitary tissue [1,3].”
BackgroundSelf-citation
Metadata
- Authors
- Baldessarini, R. J., & Tarazi, F. I.
- Venue
- Harvard Review of Psychiatry
- Published
- 1996-03
- Volume
- 3
- Issue
- 6
- Pages
- 301-325
- ISSN
- 1067-3229 (ISSN-L)
- OpenAlex
- W2142918202
- Cited by
- 112
- References
- 12
- FWCI
- 3.50
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Brain Dopamine Receptors: A Primer on Their Current Status, Basic and Clinical. https://app.cochat.ai/papers/10.3109/10673229609017200
- The paper
- Baldessarini, R. J., & Tarazi, F. I. (1996). Brain Dopamine Receptors: A Primer on Their Current Status, Basic and Clinical. Harvard Review of Psychiatry. https://doi.org/10.3109/10673229609017200
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.